Yes, Spravato can be profitable for psychiatry practices, but profitability depends on more than reimbursement alone.
The biggest factors are:
A practice can have strong patient demand and still lose money if Buy and Bill costs are too high, authorizations are delayed, or claims are underpaid.
The simplest way to think about it is:
The important word is collected.
Your billed charges do not determine profitability. What actually gets paid does.
That is why Spravato reimbursement has to be reviewed by payer, not by one average number.
For Buy and Bill practices, medication cost is one of the biggest financial factors.
Before ordering Spravato, clinics should understand:
Even a small difference in acquisition cost can become meaningful when multiplied across hundreds of treatments.
Our Spravato Billing Services are designed to simplify this process by helping practices connect drug cost, payer reimbursement, and actual collections.
Prior Authorization is not just an administrative task.
If approval is delayed, treatment is delayed.
If reauthorization is missed, revenue stops.
If authorization details do not match the claim, reimbursement may be denied.
That is why eligibility verification and Prior Authorization are two of the most important revenue drivers in a Spravato program.
As a leading Spravato Billing Services Company, Finnastra manages eligibility, Prior Authorization, reauthorization, and payer follow-up to reduce avoidable delays.
Not every revenue problem appears as a denial.
Common leakage includes:
A profitable Spravato practice needs to track both denials and underpayments.
If a payer sends less than expected and nobody reviews it, the claim may appear “paid” while the practice still loses money.
Two clinics treat the same number of Spravato patients.
Clinic A purchases medication at a higher cost, has inconsistent Prior Authorization tracking, and accepts payer payments without reviewing underpayments.
Clinic B controls acquisition cost, verifies benefits before treatment, tracks every authorization, and follows claims through full payment.
The treatment volume is identical.
The profitability is not.
That difference is why specialized Spravato billing matters.
When you work with a dedicated Spravato Billing Company like Finnastra, we focus on the full financial workflow.
We help practices:
The goal is not simply to submit more claims.
It is to protect the margin behind every treatment.
A Spravato program should regularly review:
If these numbers are not visible, it is difficult to know whether the program is truly profitable.
Is Buy and Bill profitable for Spravato?
It can be, but profitability depends on acquisition cost, payer reimbursement, claim accuracy, and payment timing.
What hurts Spravato profitability most?
High drug costs, authorization delays, denials, underpayments, and poor payer reimbursement are among the biggest risks.
Can Finnastra help review Spravato profitability?
Yes. Finnastra can review billing, reimbursement, denials, AR, Prior Authorization performance, and Buy and Bill workflows to identify where revenue is being lost.
Is Spravato Worth Adding to Your Practice?
For the right psychiatry practice, Spravato can become a strong clinical service line and a meaningful source of revenue.
But profitability comes from execution.
Practices need control over acquisition cost, payer contracts, authorization, billing accuracy, and collections.
As a Top Spravato Billing Company in U.S and a specialized partner for Spravato programs, Finnastra helps practices build that financial structure from treatment through reimbursement.
